Coulter Partners conducts successful CEO search for Nitinotes
London, October 3, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with MTIP and the Nitinotes Board to conduct a successful search for a new Chief Executive Officer (“CEO”) for Nitinotes. We are pleased to announce the placement of Lloyd Diamond in this key leadership role.
Nitinotes is a pioneer in medical technology and a leader in Innovative Obesity Treatment. The Company developed EndoZip™, a minimally invasive, fully automated endoscopic suturing system aimed at treating obesity. The EndoZip ensures consistent, safe suturing with the press of a button, representing a significant advancement in the field of Endoscopic Sleeve Gastroplasty (‘’ESG’’). Nitinotes has successfully filed for CE mark approval in early 2024, with approval anticipated by early 2025, paving the way for the Company’s European commercial launch. As Nitinotes is enhancing its operational capabilities to enter the EU market, it is also preparing a pivotal trial in the U.S. to support its global regulatory strategy.
MTIP first invested in Nitinotes in March 2018 and has continued to support the company ever since. The Swiss-based growth equity firm played a crucial role in introducing Nitinotes to Coulter Partners, enabling the search for top-tier leadership talent.
Lloyd succeeds Raz Bar-On, who will continue as General Manager (‘’GM’’) of Nitinotes Israel, overseeing operations, R&D, and regulatory functions.
Lloyd Diamond brings more than 30 years of leadership in the medical device industry, having spearheaded significant advancements in orthopedics, endoscopic, and general surgical devices. Most recently, he served as CEO of Pixium Vision S.A., where he led the development of groundbreaking bionic vision systems and strategic partnerships.
"I am honored to join Nitinotes at this pivotal time," said Lloyd Diamond, new CEO. He continued:
With obesity rates rising worldwide and over 1 billion people affected, EndoZip™ provides a critical solution to a significant global health challenge. I look forward to working with the talented team to bring this solution to more patients and healthcare providers worldwide."
John Barr, Chairman of the Board commented:
We are thrilled to welcome Lloyd to lead Nitinotes into its next chapter of innovation and growth. Building upon the foundation established and the exceptional achievements attained, his extensive experience in medical technologies positions him as an outstanding leader to advance our future initiatives.
John Barr continued, “Lloyd's appointment concludes a rigorous executive search process that MTIP initiated in collaboration with Coulter Partners. We express our deep gratitude to Coulter Partners for their exceptional support. Their expert guidance was invaluable in identifying the ideal leader for Nitinotes. Their deep understanding of our specific needs and extensive network within the market were instrumental in delivering a successful outcome. Given the complexity of this role, finding the right candidate was a challenging task, but Coulter Partners' professionalism and dedication ensured we found the perfect match."
----
Lloyd Diamond, new CEO of Nitinotes
Lloyd Diamond is a seasoned life sciences executive with over 30 years of experience in the medtech and biotech sectors. He has led successful fundraising, M&A, and IPO transactions for startups, high-growth companies, and turnarounds. Lloyd has a proven track record in driving the commercialization of disruptive medical technologies across various clinical segments, including orthopedics, ophthalmology, and urology, in global markets. He has extensive experience in managing sales organizations, negotiating agreements with key healthcare institutions, and securing reimbursement policies. Prior to joining Nitinotes, Lloyd served as CEO at Pixium Vision, where he advanced groundbreaking bionic vision systems. Lloyd holds an MBA in International Finance & Marketing and is fluent in several languages.
